Long-Term Safety and Tolerability of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease: An Open-Label Extension Study for Subjects Completing Study M10-985

Trial Profile

Long-Term Safety and Tolerability of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease: An Open-Label Extension Study for Subjects Completing Study M10-985

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 May 2016

At a glance

  • Drugs Nelonicline (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 25 Mar 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 04 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 22 Jun 2013 Planned number of patients changed from 350 to 410 as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top